This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
M.E. Anderson , S.M. Al-Khatib , D.M. Roden , (2002). Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. American Heart Journal, 144, 769–781.
K. Auret , C. Roger Goucke , K.F. Ilett , (2006). Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring, 28, 359–366.
C. Centeno & F. Vara (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of Pain Palliative Care Pharmacotherapy, 19(2), 7–12.
S. Derby , J. Chin , & R.K. Portenoy (1998). Systemic opioid therapy for chronic cancer pain: Practical guidelines for converting drugs and routes of adminsistration. CNS Drugs, 9, 99–109.
K.R. Dyer & J.M. White (1997). Patterns of symptoms complaints in methadone maintenance patients. Addiction, 92, 1445–1455.
G.B. Ehret , C. Voide , M. Gex-Fabry , (2006). Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Archives of Internal Medicine, 166, 1280–1287.
D.R. Fitzgibbon & L.B. Ready (1997). Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain, 73, 259–261.
A. Garson (1993). How to measure the QT interval—What is normal. American Journal of Cardiology, 72, 14B–16B.
C.A. Kornick , M.J. Kilborn , J. Santiago-Palma , (2003). QTc interval prolongation associated with intravenous methadone. Pain, 105, 499–506.
M.J. Krantz & P.S. Mehler (2006) QTc prolongation: Methadone's efficacy-safety paradox. Lancet, 368, 556–557.
P.G. Lawlor , K.S. Turner , J. Hanson , (1998). Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer, 82, 1167–1173.
M.K. Makin (2000). Subcutaneous methadone in terminally-ill patients [letter]. Journal of Pain and Symptom Management, 19, 237–238.
P.L. Manfredi , D. Borsook , S.W. Chandler , (1997). Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain, 70, 99–101.
P. Mathew & P. Storey (1999). Subcutaneous methadone in terminally ill patients: Manageable local toxicity. Journal of Pain and Symptom Management, 18, 49–52.
S. Mercadante , A. Casuccio , & L. Calderone (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology, 17, 1–6.
J.S. Morley & M.K. Makin (1998). The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews, 5, 51–58.
R. Payne & C.E. Inturrisi (1985). CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sciences, 37, 1137–1144.
J. Santiago-Palma , N. Khojainova , C. Kornick , (2001). Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer, 92, 1919–1925.
R. Sekine , A.M.T. Eugenia , N. Coyle , (2007). The successful use of parenteral methadone in a patient with a prolonged QTc interval. Journal of Pain and Symptom Management, 34, 566–569.